Evidence map›Paper›PMID 33621404›Full record

Trial reportAnnals of clinical and translational neurology2021

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial.

Robert A Bermel, Emmanuelle Waubant, Gabriel Pardo, Ann Bass, Pavle Repovic, Scott Newsome, John W Lindsey, Deidre Kile, Ashish Pradhan, Bruno Musch and 1 more

Open access · goldAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Robert A BermelMellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Emmanuelle WaubantWeill Institute for Neurosciences, University of California, San Francisco, CA, USA.ORCID 0000-0001-5188-0157
Gabriel PardoMultiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Ann BassNeurology Center of San Antonio, San Antonio, TX, USA.
Pavle RepovicSwedish Neuroscience Institute, Seattle, WA, USA.
Scott NewsomeDivision of Neuroimmunology and Neuroinfectious Diseases, Johns Hopkins Hospital, Baltimore, MD, USA.
John W LindseyDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Deidre KileGenentech, Inc., South San Francisco, CA, USA.
Ashish PradhanGenentech, Inc., South San Francisco, CA, USA.
Bruno MuschGenentech, Inc., South San Francisco, CA, USA.
Aram ZabetiUC Waddell Center for Multiple Sclerosis, Cincinnati, OH, USA.
Cleveland Clinic · USJohns Hopkins Hospital · USOklahoma Medical Research Foundation · USSwedish Medical Center · USThe University of Texas Health Science Center at Houston · USUniversity of California, San Francisco · USUrology San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing-remitting multiple sclerosis who had a suboptimal response to previous disease-modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing four doses of OCR per initial US prescribing recommendations in the main study, participants in the substudy (N = 129) received a fifth dose over a 2-h duration (vs. 3.5 h). Infusion-related reactions occurred in 12.4% of patients. None were severe, life-threatening or led to treatment discontinuation. Shorter infusion time did not change the safety profile of OCR. Clinicaltrials.gov (NCT0237856).

Indexed as

AdultAntibodies, Monoclonal, HumanizedFemaleFollow-Up StudiesHumansImmunologic FactorsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingOutcome Assessment, Health CareAntibodies, Monoclonal, HumanizedImmunologic Factorsocrelizumab

Identifiers

PMID33621404
PMCPMC7951110
OpenAlexW3133022188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.